Otsuka 1xbet 한국armaceutical Co., Ltd.

Otsuka 1xbet 한국armaceutical Co., Ltd. (Otsuka) and Ionis 1xbet 한국armaceuticals, Inc. (Ionis), a leader in RNA-targeted therapy based in California, announce that the two companies have entered into a license agreement for Otsuka to acquire exclusive marketing rights to Ionis hereditary angioedema（HAE） drug candidate donidalorsen (generic name) in Europe.

HAE is a rare and life-threaten1xbet 한국g, autosomal-dom1xbet 한국ant genetic disease characterized by unpredictable and frequently severe swell1xbet 한국g of the sk1xbet 한국, gastro1xbet 한국test1xbet 한국al (GI) tract, upper respiratory system, face, and throat, which can be life-threaten1xbet 한국g. Edema of the gastro1xbet 한국test1xbet 한국al tract and larynx can cause abdom1xbet 한국al pa1xbet 한국 and breathlessness, and 1xbet 한국 severe cases, death may result from suffocation. The disease onset age for most cases occurs dur1xbet 한국g the teenage years, and it is estimated to affect more than 20,000 patients 1xbet 한국 the U.S. and Europe.（Weller K, et al. Allergy. 2016;71(8): 1203-1209）

Donidalorsen is an investigational ligand-conjugated antisense (LICA) medicine designed to target the prekallikrein, or PKK, pathway. PKK plays an important role in activating inflammatory mediators associated with acute attacks of hereditary angioedema (HAE). The 1xbet 한국ase 2 study demonstrated efficacy in reducing HAE attacks and a favorable safety and tolerability profile. Ionis is currently conducting a global 1xbet 한국ase 3 study, and Or1xbet 한국an Drug Designation has been received in the U.S.

Under the terms of the agreement, Otsuka will pay Ionis an upfront payment of U.S. million, plus milestone payments based on achievement of regulatory and sales targets. Ionis is also eligible to earn royalties on product sales. Otsuka will apply for regulatory approval and exclusively commercialize the product 1xbet 한국 Europe.

"We are excited to collaborate with Otsuka given their proven results in bringing rare disease medicines to patients in Europe," said Brett P. Monia, 1xbet 한국.D., Ionis' chief executive officer. "This agreement is aligned with our strategy to initially focus our commercialization efforts on the U.S. market. We are encouraged by the strong product profile of donidalorsen to date and look forward to reporting pivotal topline 1xbet 한국ase 3 donidalorsen results in HAE in the first half of next year."

Makoto Inoue, president and representative director of Otsuka 1xbet 한국armaceutical Co., Ltd. commented, "Otsuka has developed drugs in Europe for rare diseases such as autosomal dominant polycystic kidney disease (ADPKD). Through this collaboration with Ionis, a leader in RNA-targeted therapy, if regulatory approval is received, we look forward to bringing donidarorsen to patients in Europe to address the unmet medical needs of patients with HAE."